No Carolina / New York / Florida        Ph: 561.316.3330

Single Use Barriers: Study Finds Clinically Superior to Disposable Stethoscopes

What To Know

  •   While the persistent risk of HAI with disposable stethoscopes has been established, this study is the first to describe the compromised performance associated with their use compared to an emerging alternative in aseptic single-use disk cover barriers.
  •   The stethoscope is also a proven vector of disease transmission, with CDC cleaning guidelines that are incompatible with the intensity of stethoscope use and the high-paced workflow in clinical settings.

January 11, 2021

Single Use Barriers: A study described in a letter to the editor in the January issue of Mayo Clinic Proceedings entitled “Aseptic Disposable Stethoscope Barrier: Acoustically Invisible and Superior to Disposable Stethoscopes” found that aseptic disk cover barriers from AseptiScope (www.diskcover.com), previously proven to block the growth of dangerous pathogens on stethoscope diaphragms, are acoustically invisible and allow for 100% diagnostic accuracy.

In contrast, the same study reported that disposable stethoscopes were found to present an 11% misdiagnosis rate for serious clinical conditions that may have auscultatory findings such as systolic and diastolic heart murmurs.

The stethoscope commonly referred to as the clinician’s “third hand,” is the most frequently used medical instrument with over 5.5 billion annual auscultations in the US alone.  The stethoscope is also a proven vector of disease transmission, with CDC cleaning guidelines that are incompatible with the intensity of stethoscope use and the high-paced workflow in clinical settings.  A current approach to reduce the spread of healthcare-acquired infection (HAI) is the use of disposable stethoscopes.  While the persistent risk of HAI with disposable stethoscopes has been established, this study is the first to describe the compromised performance associated with their use compared to an emerging alternative in aseptic single-use disk cover barriers.

“Failure to correctly identify auscultatory sounds 11% of the time presents a tremendous clinical and economic cost to the healthcare system,” said Sarathi Kalra, MD, MPH principal investigator of this study who is also an Assistant Professor and Research Director in the Department of Emergency Medicine at the University of South Alabama, Mobile.  “Such a significant error rate creates a potential liability for health care providers who rely on accurate clinical assessments to develop appropriate, and often time-sensitive, treatment plans. The full impact of a missed diagnosis using disposable stethoscopes extends far beyond financial implications. Added morbidity and mortality from a delayed or missed diagnosis can often times lead to irreversible outcomes, especially in the acute care setting where disposable stethoscopes are frequently used,” Dr. Kalra added.

Study Design and Results
This prospective evaluation employed Littmann 3200 recording stethoscopes (3M), a simulation mannequin (iSTAN, CAE), disk cover barriers (AseptiScope), and disposable stethoscopes (Proscope 665, ADC. Inc.).  Twenty-eight physicians performed auscultations in prespecified locations and listened for 15 seconds of respiratory wheezes, normal heart sounds, systolic murmurs, and diastolic murmurs.  Physicians were blinded to the presence of barriers and received sounds in random order.  Digital audio files were analyzed for amplitude differences (Logic Pro X, Apple Inc.), with and without a disk cover barrier in place.

Unblinded physicians then used Littmann stethoscopes with barriers and disposable stethoscopes without barriers and auscultation accuracy was recorded.  The Wilcoxon rank sum test was used to compare amplitude differences among groups and McNemar’s test was used to compare diagnostic accuracy.

In 800 matched observations of Littmann stethoscopes with and without disk cover barriers, there were no differences in sound amplitude (P=1.0) across all sounds.  Diagnostic accuracy of 110 auscultations using the Littmann plus disk cover barrier was 100%.  The 110 auscultations with the disposable stethoscopes saw an error rate of 10.9% (12 of 110) with misinterpretation of 9 systolic murmurs as occurring during diastole and 3 diastolic murmurs identified as occurring during systole.

In subjective evaluation, 95% of physicians reported a preference for their personal stethoscope with a disk cover barrier over the disposable stethoscope.

“This important study establishes the clinical and economic advantages that our DiskCover System delivers over the use of disposable stethoscopes,” said Scott Mader, CEO, and co-founder of AseptiScope.  “Our innovation allows clinicians to use their personal stethoscopes, with no loss of fidelity, to make critical clinical diagnoses accurately while protecting patients from exposure to dangerous pathogens.  This study adds to an increasing body of evidence establishing The DiskCover System a clinically significant advance in the challenge of stethoscope hygiene,” Mader added.

 

Latest

Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

The research, presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting, included a registrational Phase 3 trial and an integrated safety analysis of six clinical studies, as well as a real-world analysis of current treatment options and gaps in the clinical management of patients with newly-diagnosed LDH.

ADVERTISE

spot_img

Don't miss

Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

The Future of Biotechnology: Insights Into Cutting-Edge Developments

The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.

Advancing Patient Care: LyGenesis Doses First Patient in Phase 2a Trial

"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."

The Vital Role of CDMOs in Bringing New Therapies to Market

The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.

Revolutionary T-Cell Analysis Unveiled for Early Cancer Detection at AACR | Reports Serum Detect

Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy